- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lunit Inc (328130)
The Lunit share price today is 15,450, view KQ 328130 stock exchange data. Track the latest Lunit share price with real-time updates on 328130 stock performance including market cap, day range, 52-week range and dividend yield. Access 328130 charts, earnings dates and analyst estimates to support your investment decisions.
15,450
+780(+5.32%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13,150
16,050
52 wk Range
8,180
24,550
Earnings results expected in 5 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13,15016,050
52 wk Range
8,18024,550
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
328130 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Sell
Price Target
10,150
Downside
-34.30%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock generally trades with high price volatility
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
0 Buy
0 Hold
1 Sell
Ratings:
1 analysts
Overall Consensus
Strong Sell
Analysts 12-Month Price Target:
Average 10,150
(-34.30% Downside)
Earnings
Latest Release
11-08-2026
EPS / Forecast
-325.00 / --
Revenue / Forecast
26.3B / --
Compare 328130 to Peers and Sector
Metrics to compare | 328130 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship328130PeersSector | |
|---|---|---|---|---|
P/E Ratio | −20.7x | −3.1x | −0.2x | |
PEG Ratio | −0.69 | 0.04 | 0.00 | |
Price/Book | 3.5x | 1.1x | 2.6x | |
Price / LTM Sales | 12.5x | 3.4x | 2.8x | |
Upside (Analyst Target) | −34.3% | 75.3% | 65.6% | |
Fair Value Upside | Unlock | 33.9% | 10.0% | Unlock |
Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations; with Agilent Technologies Inc. to create advanced solutions that meet the demand of novel and complex biomarker assays in drug development; with Daiichi Sankyo Company, Limited to accelerate biomarker discovery and translational research; and with Summit Therapeutics Inc. to apply AI-powered SCOPE IO pathology platform for tumor microenvironment analysis in immuno-oncology development. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Lunit (328130) Share Price Today?
The Lunit share price today is 15,450.
What is the current Lunit (328130) share price and day range?
As of 07-11-2026, the Lunit share price is 15,450, with a previous close of 15,450. The share price has ranged from 13,150 to 16,050 today, while the 52-week range spans from 8,180 to 24,550.
What Is the Lunit Market Cap?
As of today, Lunit market cap is 1.15T.
What Is the Lunit (328130) Share Price Target?
The average 12-month share price target for Lunit is 10,150, with a high estimate of 11300 and a low estimate of 9000. 0 analysts recommend buying, while 1 suggest selling, with an overall rating of Strong Sell and -34.30% Downside potential.
What Is Lunit's Earnings Per Share (TTM)?
The Lunit EPS (TTM) is -886.17.
When Is the Next Lunit Earnings Date?
Lunit will release its next earnings report on 12-11-2026.
From a Technical Analysis Perspective, Is 328130 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
What Stock Exchange Does Lunit Trade On?
Lunit is listed and trades on the KOSDAQ.
What Is the Stock Symbol for Lunit?
The stock symbol for Lunit is "328130."
How Many Times Has Lunit Stock Split?
Lunit has split 2 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.